Anticoagulant test
US6063584A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Nov 21, 1997 |
| Grant date | May 16, 2000 |
| Priority date | — |
| Expiry date | Nov 21, 2017 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/86
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention is a method for identifying a patient at risk to developing fibrinogen receptor antagonist-induced thrombocytopenia which comprises incubating patient plasma with a GPIIb/IIIa receptor:GPIIb/IIIa receptor antagonist complex to form a GPIIb/IIIa receptor:GPIIb/IIIa receptor antagonist:plasma antibody complex, incubating the GPIIb/IIIa receptor:GPIIb/IIIa receptor antagonist:plasma antibody complex with a secondary anti-human detectable antibody to form a GPIIb/IIIa receptor:GPIIb/IIIa receptor antagonist:plasma antibody:secondary anti-human detectable antibody complex, and detecting the presence of the secondary anti-human detectable antibody in the GPIIb/IIIa receptor:GPIIb/IIIa receptor antagonist:plasma antibody:secondary anti-human detectable antibody complex.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.